Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Testosterone
Drug ID BADD_D02170
Description Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.[A187114,L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone was isolated from samples and also synthesized in 1935.[A186943]
Indications and Usage Testosterone is indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995]
Marketing Status approved; investigational
ATC Code G03BA03
DrugBank ID DB00624
KEGG ID D00075
MeSH ID D013739
PubChem ID 6013
TTD Drug ID D06XMU
NDC Product Code 0832-1120; 65089-0050; 43598-304; 49884-418; 63629-8455; 63629-9310; 0591-2925; 38779-2936; 43647-568; 43742-1436; 73774-014; 76003-1083; 43742-1242; 0245-0871; 62332-552; 70700-112; 76420-685; 76420-687; 76420-699; 24979-130; 45802-610; 0051-8462; 64380-151; 68180-943; 69097-363; 0591-2363; 0603-7831; 0009-5020; 44132-006; 49452-7658; 64025-0010; 45802-281; 0245-0872; 0023-5992; 63629-2125; 64380-152; 66887-001; 0591-2114; 0591-2924; 0591-2926; 0591-3216; 0832-1121; 51927-0267; 70492-002; 76420-684; 0009-0074; 12875-8248; 22552-0009; 49452-7652; 60592-721; 60870-0251; 16714-967; 17139-562; 63629-2124; 68180-941; 44132-008; 48087-0113; 51552-0029; 42667-5511; 63481-183; 63629-2352; 69238-1013; 0591-3217; 0591-3524; 38779-0163; 38779-2598; 82393-113; 24979-078; 45802-366; 66887-004; 51552-0564; 62991-2150; 76420-686; 16714-969; 45802-754; 49884-510; 62332-488; 69339-158; 0591-2921; 49452-7657; 16714-968; 0023-5990
UNII 3XMK78S47O
Synonyms Testosterone | 17-beta-Hydroxy-4-Androsten-3-one | 17 beta Hydroxy 4 Androsten 3 one | Androtop | Histerone | Sterotate | Sustanon | Androderm | Testoderm | Testolin | Testopel | Testosterone Sulfate | AndroGel | 8-Isotestosterone | 8 Isotestosterone | 17-beta-Hydroxy-8 alpha-4-Androsten-3-one | 17 beta Hydroxy 8 alpha 4 Androsten 3 one | Andropatch | Testim
Chemical Information
Molecular Formula C19H28O2
CAS Registry Number 58-22-0
SMILES CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hepatobiliary disease09.01.08.003---
Leukoplakia08.01.06.013; 23.01.06.002---
Hyperlipidaemia14.08.03.0010.000591%
Renal impairment20.01.03.010---
Sinus disorder22.04.06.0020.000554%
Unevaluable event08.01.03.0510.002399%-
Non-cardiac chest pain08.01.08.006; 22.12.02.0090.000091%
Peripheral arterial occlusive disease24.04.03.0100.000245%-
Arterial occlusive disease24.04.02.0210.000727%-
Chorioretinopathy06.09.01.0060.000364%-
Implant site pain08.02.02.008; 12.07.02.0080.002745%-
Application site induration08.02.01.014; 12.07.01.015---
Choroidal effusion06.09.01.0080.000091%-
Application site exfoliation08.02.01.022; 12.07.01.022; 23.03.07.0070.000618%-
Procedural pain08.01.08.009; 12.02.05.007---
Application site burn08.02.01.038; 12.07.01.038; 23.03.11.0130.000509%-
Bronchial hyperreactivity22.03.01.016---
Thyroid cancer05.02.05.001; 16.24.03.0010.000091%-
Gingival erythema07.09.13.006---
Oral disorder07.05.01.005---
Vulvovaginal burning sensation21.08.02.007---
Brain injury17.11.01.003; 19.07.03.0070.000364%-
Androgenetic alopecia05.05.04.001; 23.02.02.002---
Brain stem stroke17.08.01.033; 24.04.06.0240.000182%-
Pulmonary oil microembolism12.02.07.008; 22.06.02.007; 24.01.06.007---
Hypoxic-ischaemic encephalopathy17.13.02.006; 22.02.02.011; 24.04.06.0210.000182%-
Sensitisation08.01.05.009; 10.02.01.0120.000309%-
Korsakoff's syndrome14.12.02.007; 17.03.02.008; 19.20.05.002---
Prostatic dysplasia21.04.01.007---
Peripheral artery thrombosis24.01.02.0100.000318%-
The 17th Page    First    Pre   17 18 19    Next   Last    Total 19 Pages